Literature DB >> 27273340

Extending the indication for robot-assisted retroperitoneal partial nephrectomy to antero-lateral renal tumors.

Hee Youn Kim1, Hyun-Sop Choe1, Dong Sup Lee1, Jae Mo Yoo1, Seung-Ju Lee1.   

Abstract

BACKGROUND: Robot-assisted retroperitoneal partial nephrectomy (RARPN) is typically employed for posterior renal tumors. This work aimed to extend the indication of RARPN to patients with selected antero-lateral renal tumor.
METHODS: Patients who underwent RARPN between December 2013 and September 2015 at the authors' institution were enrolled. Two intersecting lines were drawn on an axial CT image to define the medial/lateral nature of anterior renal tumors. Patients with antero-lateral tumor and posterior tumor were compared.
RESULTS: Antero-lateral tumors constituted 56.1% (32/57) of the total cases. The perioperative outcomes between the two groups were comparable. Although the operation time was longer for the antero-lateral tumor group, it did not show statistical significance. No cases had positive margins. There was one case of Clavien-Dindo grade IIIa complication in the antero-lateral tumor group.
CONCLUSIONS: RARPN is a safe and effective procedure not only for posterior renal tumors but also for carefully selected antero-lateral renal tumors.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  partial nephrectomy; renal cell carcinoma; robotics

Mesh:

Year:  2016        PMID: 27273340     DOI: 10.1002/rcs.1755

Source DB:  PubMed          Journal:  Int J Med Robot        ISSN: 1478-5951            Impact factor:   2.547


  2 in total

Review 1.  Frontiers in robot-assisted retroperitoneal oncological surgery.

Authors:  Wesley W Ludwig; Michael A Gorin; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

2.  Novel Gerota-edge-sling technique facilitates retroperitoneal robot-assisted partial nephrectomy: a comparative study.

Authors:  Wei Chen; Qixiang Fang; Haomin Ren; Lei Ma; Jin Zeng; Shangshu Ding; Dapeng Wu
Journal:  BMC Urol       Date:  2022-08-20       Impact factor: 2.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.